All pages
Jump to navigation
Jump to search
- ACADVL
- ACAM-FLU-A
- ACAS
- ACAT1
- ACAT2
- ACBD3
- ACC
- ACC-2017 Pregnancy - CHD
- ACC/AHA guideline on the secondary prevention of hypercholestrolemia
- ACC/AHA guidelines-recommendations for permanent pacing in patients with congenital heart disease
- ACC/AHA guidelines for cardiac radionuclide imaging (2003)
- ACC/AHA guidelines for dextro-transposition of great arteries
- ACC/AHA guidelines for evaluation of unoperated patients with atrial septal defects
- ACC/AHA guidelines for reproduction in patients with atrial septal defect
- ACC/AHA guidelines inferior vena cava filter
- ACC/AHA guidelines surgical embolectomy
- ACC/AHA recommendations for closure of patent ductus arteriosus
- ACC/AHA recommendations for evaluation of patients with unoperated patent ductus arteriosus
- ACC/AHA recommendations for evaluation of the unoperated patient in atrial septal defect
- ACC/AHA recommendations for interventional and surgical therapy in atrial septal defect
- ACC/AHA recommendations for reproduction in dextro-transposition of the great arteries
- ACC/AHA recommendations for reproduction in levo-transposition of the great arteries
- ACC/AHA recommendations for surgery in adults with previous repair of tetralogy of fallot
- ACC/AHA recommendations for surgical intervention in L-transposition of the great arteries
- ACCELERATE Trial
- ACCELERATE trial
- ACCENT
- ACCEPT
- ACCESS
- ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 Appropriateness Criteria for Cardiac Magnetic Resonance Imaging
- ACCF/ASNC appropriateness criteria for SPECT-MPI (2005)
- ACCLAIM
- ACCN1
- ACCN2
- ACCN3
- ACCOMPLISH
- ACCORD
- ACCP guidelines classification scheme
- ACCRA Cost of Living Index
- ACCT
- ACCURACY
- ACC / AHA Guidelines-Recommendations for Permanent Pacing in Children, Adolescents, and Patients With Congenital
- ACC / AHA Guidelines-Recommendations for Permanent Pacing in Children, Adolescents, and Patients With Congenital heart disease
- ACC 2009 schedule
- ACC 2010 schedule
- ACC 2011 Schedule
- ACC 2012 schedule
- ACC 2013 schedule
- ACC 2014 schedule
- ACC AHA Guideline on Secondary prevention
- ACC AHA Guideline on the Assessment of Cardiovascular Risk
- ACC AHA Guideline on the secondary prevention
- ACC AHA Guideline on the secondary prevention of hypercholestrolemia
- ACC AHA Guidelines Classification Scheme
- ACC AHA guideline on summary of Key Recommendations for the Treatment of Blood Cholesterol to Reduce ASCVD Risk in Adults
- ACC AHA guideline on the primary prevention
- ACC AHA guideline on the primary prevention of hypercholestrolemia
- ACC AHA guideline on the treatment of blood cholesterol
- ACC AHA guideline on the treatment of blood cholesterol LDL and non-HDL treatment goals
- ACC AHA guideline on the treatment of blood cholesterol Managing Statin Therapy
- ACC AHA guideline on the treatment of blood cholesterol heart failure and hemodialysis
- ACC AHA guideline on the treatment of blood cholesterol intensity of statin therapy in primary and secondary prevention
- ACC AHA guideline on the treatment of blood cholesterol primary prevention
- ACC AHA guideline on the treatment of blood cholesterol safety
- ACC AHA guideline on the treatment of blood cholesterol secondary prevention
- ACC AHA guideline on the treatment of blood cholesterol statin treatment
- ACC AHA guidelines classification scheme
- ACC AHA guidelines for evaluation of unoperated patients with atrial septal defects
- ACC AHA recommendations for evaluation of the unoperated patient in atrial septal defect
- ACC AHA recommendations for surgery in adults with previous repair of tetralogy of fallot
- ACC AMI GAP
- ACC Schedule 2015
- ACD (gene)
- ACE
- ACE-I
- ACE-inhibitor
- ACE-inhibitors
- ACEI
- ACEIs
- ACER1
- ACER2
- ACER3
- ACES
- ACES (buffer)
- ACES (computational chemistry)
- ACES (nutritional supplement)
- ACE (Carotid Endarterectomy)
- ACE I
- ACE Inhibition
- ACE Inhibitor
- ACE inhibition
- ACE inhibitor
- ACE inhibitor-induced cough
- ACE inhibitors
- ACF (gene)
- ACG2
- ACGME
- ACGT
- ACGT-containing element gene transcriptions
- ACG guidelines classification scheme
- ACH
- ACHE
- ACHM
- ACHOO syndrome
- ACIMED
- ACIN1
- ACIP
- ACKR3
- ACL
- ACLS
- ACLS cases
- ACLS core cases
- ACLS guidelines
- ACM
- ACME
- ACME-2
- ACML
- ACNES
- ACO1
- ACO2
- ACOP regimen
- ACORN
- ACOT1
- ACOT11
- ACOT12
- ACOT13
- ACOT2
- ACOT4
- ACOT6
- ACOT7
- ACOT8
- ACOX1
- ACOX3
- ACP1
- ACP2
- ACRE
- ACRRM
- ACRV1
- ACR Practice Guideline for the Performance and Interpretation of Cardiac Magnetic Resonance Imaging (MRI)
- ACR practice guideline for the performance and interpretation of cardiac magnetic resonance imaging (MRI)
- ACS
- ACSBG1
- ACSBG2
- ACSF3
- ACSL1
- ACSL3
- ACSL4
- ACSL5
- ACSL6
- ACSL6 gene
- ACSM2B
- ACSM3
- ACSS2
- ACSS3
- ACST
- ACS III
- ACS National Historical Chemical Landmarks
- ACS style
- ACT
- ACT-UP
- ACTA1
- ACTA2
- ACTB
- ACTC1
- ACTG1
- ACTG2
- ACTH
- ACTH-40 HP
- ACTH-80
- ACTH-secreting tumor
- ACTH-secreting tumors
- ACTH Deficiency
- ACTH Gel
- ACTH deficiency
- ACTH receptor
- ACTH resistance
- ACTH stimulation test
- ACTHoma
- ACTION
- ACTION ICU risk score
- ACTIVATE
- ACTIVE A
- ACTIVE A Trial
- ACTIVE W
- ACTIVE W Trial
- ACTIV in CHF
- ACTL6A
- ACTL6B
- ACTL7A
- ACTL8
- ACTN1
- ACTN3
- ACTN3 (gene)
- ACTR1A
- ACTR1B
- ACTR2
- ACTR3
- ACTR3B
- ACT trial
- ACUITY
- ACUITY HORIZONS
- ACUITY HORIZONS bleeding criteria
- ACUITY PCI: 30-day and 1-Year Results
- ACUITY Timing Trial
- ACUTE
- ACUTE II
- ACVBP-R regimen
- ACVR1
- ACVR1B
- ACVR1C
- ACVR2A
- ACVR2B
- ACVRL1
- ACY1
- ACY2 Deficiency
- ACY2 deficiency
- ACYP1
- ACYP2
- AC regimen
- ACh
- ACh receptor
- AD
- AD-36
- AD-mix
- AD16 (gene)
- AD4
- ADALINE
- ADAM
- ADAM10
- ADAM11
- ADAM12
- ADAM15
- ADAM17
- ADAM18
- ADAM19
- ADAM2
- ADAM22
- ADAM23
- ADAM28
- ADAM33
- ADAM7
- ADAM7 mRNA
- ADAM8
- ADAM9
- ADAMTS-13
- ADAMTS1
- ADAMTS10
- ADAMTS12
- ADAMTS13
- ADAMTS17
- ADAMTS2
- ADAMTS3
- ADAMTS4
- ADAMTS5
- ADAMTS6
- ADAMTS7
- ADAMTS8
- ADAMTS9
- ADAMTSL1
- ADAMTSL4
- ADAM metallopeptidase with thrombospondin type 1 motif, 10
- ADAM protein
- ADAPT
- ADAR
- ADARB1
- ADARB2
- ADA guidelines classification scheme
- ADCC
- ADCK3
- ADCS
- ADCY1
- ADCY10
- ADCY2
- ADCY3
- ADCY4
- ADCY5
- ADCY6
- ADCY7
- ADCY8
- ADCY9
- ADCYAP1R1
- ADD
- ADD/ADHD
- ADD1
- ADD2
- ADD3
- ADE
- ADEKs
- ADEM
- ADEMEX
- ADEPT
- ADFP
- ADH
- ADH1A
- ADH1B
- ADH1C
- ADH4
- ADH5
- ADH6
- ADH7
- ADHD
- ADHD predominantly hyperactive-impulsive
- ADHD predominantly inattentive
- ADHF
- ADH inappropriate
- ADI1
- ADIOS
- ADK (gene)
- ADL
- ADLS
- ADLs
- ADM2
- ADME
- ADME-Tox
- ADMIRAL
- ADMIT
- ADNFLE
- ADNP (gene)
- ADOC regimen
- ADONIS
- ADOPT
- ADOPT-A
- ADP
- ADP-dependent medium-chain-acyl-CoA hydrolase
- ADP-dependent short-chain-acyl-CoA hydrolase
- ADP-glyceromanno-heptose 6-epimerase
- ADP-phosphoglycerate phosphatase
- ADP-ribose diphosphatase
- ADP-ribosyl-(dinitrogen reductase) hydrolase
- ADP-ribosylation
- ADP-specific glucokinase
- ADP-specific phosphofructokinase
- ADP-sugar diphosphatase
- ADP-thymidine kinase
- ADPKD
- ADPRHL1
- ADPRHL2
- ADP deaminase
- ADP receptor
- ADP ribose
- ADP ribosylation factor
- ADR
- ADRA2A
- ADRA2B
- ADRA2C